MTAP and myxofibrosarcoma: Since several antimetabolites targeting purine synthesis are available and additional drugs are in development [32–34], the findings of this study suggest that MTAP-deficient myxofibrosarcomas may benefit from the chemoselective targeting of the defects in methionine-adenine recycling and AMP synthesis.